MAP2K7 and pleomorphic xanthoastrocytoma: The presented patient experienced a progression-free interval of 3 years in recurrent anaplastic PXA upon therapy consisting of interstitial brachytherapy and adjuvant treatment with combined BRAF/MEK inhibitors.